Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Open-label, Controlled Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA

Next Previous
Trial Profile

A Multicenter, Randomized, Open-label, Controlled Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sinapultide (Primary)
  • Indications Neonatal respiratory distress syndrome
  • Focus Adverse reactions
  • Sponsors Windtree Therapeutics

    • Most Recent Events

    • 09 May 2019 According to a Windtree Therapeutics media release, new post-hoc, pooled analysis of two randomized, controlled phase 2 studies (NCT02528318 and NCT02636868) of premature infants with respiratory distress syndrome, were presented at the Pediatric Academic Societies (PAS) Meeting (2019).
    • 09 May 2019 Results of new post-hoc, pooled analysis of two randomized, controlled phase 2 studies (NCT02528318 and NCT02636868) of premature infants with respiratory distress syndrome, presented in a Windtree Therapeutics media release.
    • 28 Dec 2017 According to a Windtree Therapeutics media release, updated results of this trial will be discussed in conference call and live webcast on January 4, 2018.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top